From Market to Discovery and Back: The Value of Early Commercialization
Global research report - Vision & Reality 6th Edition.
![]()
- File size:
756.73 KB - Published on:
2007-02-21 03:50 PM
As the pharmaceutical industry contends with reduced periods of exclusivity, aggressive generic competition, increased regulation and the prevalence of managed care, many companies are turning to early commercialization to boost the return on investment of research & development.
The 6th Edition of Capgeminiās Vision & Reality Study, From Market to Discovery and Back: The Value of Early Commercialization is based on input from 200 leading industry executives from the pharmaceutical and biotech sectors across Europe, North America, and Asia.
Please sign-in to download the document.
No account? Register with us!
